ObjectiveTo evaluate antihypertensive efficacy and safety of different zilebesiran dosing regimens. Design, Setting, and ParticipantsThis phase 2, randomized, double-blind, dose-ranging study of zilebesiran vs placebo was performed at 78 sites across 4 countries. Screening initiation occurred in July ...
Zilebesiran In Combination With A Standard-of-care Antihypertensive In Patients With Inadequately Controlled Hypertension - Primary Results From The Phase 2 KARDIA-2 Study Zilebesiran联合标准降压治疗对高血压控制不充分患者的降压作用...
Zilebesiran In Combination With A Standard-of-care Antihypertensive In Patients With Inadequately Controlled Hypertension - Primary Results From The Phase 2 KARDIA-2 Study Zilebesiran联合标准降压治疗对高血压控制不充分患者的降压作用 (KARDIA-2 试验) Akshay S. Desai教授公布KARDIA-2研究结果(罗江滢 摄自...
CONSISTENT ANTIHYPERTENSIVE EFFICACY OF THE RNA INTERFERENCE THERAPEUTIC ZILEBESIRAN: SUBGROUP RESULTS FROM THE KARDIA-1 PHASE 2 STUDY IN PATIENTS WITH HYPERTENSION Author links open overlay panelMANISH SAXENA, Akshay S. Desai, Michel Azizi, Anil Gupta, Jongtae Lee, Daniel Stiglitz, Nune Makarova, ...
The study found that Kardia 12L enabled rapid acquisition of resting ECG information, and concluded "this approach has significant implications for rapid ECG diagnosis in clinical practice." The poster can be accessedhere. Additional Features
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk Nov 11, 2023 –Zilebesiran Met Primary Endpoint Demonstrating Up to 16.7 mmHg Pl...
In the Phase 2 KARDIA-1 study, single subcutaneous (SC) doses of zilebesiran monotherapy significantly reduced 24-hr mean ambulatory and office systolic blood pressure (SBP) from baseline to Months 3 and 6 versus placebo. The objective of KARDIA-2, a Phase 2 randomized, double-blind, ...
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
During the 6-week study period, ILR monitoring detected AF in 2 patients. The Kardiamobile strategy identified one of these patients, who had a prolonged, symptomatic paroxysm. The other individual had short episodes of AF lasting less than 30 seconds, that were asymptomatic. Table 1 compares ...
In den letzten Jahren finden strukturelle kardiale Interventionen zunehmend Anwendung in der klinischen Routine. Trotz der raschen Einführung und Weit